GENE ONLINE|News &
Opinion
Blog

2022-01-20| Asia-PacificFunding

APAC CRO Novotech Mulls IPO after $255 Million Round

by Joy Lin
Share To

Asia-Pacific contract research organization (CRO) Novotech Health Holdings is mulling an IPO in the US or Hong Kong after it raised $255 million in a financing round that valued the firm at $3 billion, reported Bloomberg Wednesday. 

Novotech’s new plans come after the firm cancelled a planned September IPO that would have seen it raise $700 million on the Hong Kong stock exchange, due to volatile market conditions. 

Novotech Holdings operates integrated labs and Phase 1 facilities and provides services for drug and clinical development. It was formed from a 2020 merger between Novotech in Singapore and Australia and PPC in mainland China. 

In addition to its $255 million financing round, Novotech also confirmed a $505 million debt refinancing. The fundraising brought in multiple new investors and saw participation from all existing shareholders. Novotech added that TPG, a private equity firm, remains its controlling stockholder. 

TPG went public on the Nasdaq last week, raising over $1 billion. The public float valued the company at over $9.5 billion. 

Related Article: GeneOnline’s Top 10 Hong Kong Biotech IPOs of 2021

Novotech to Use Proceeds for Expansion and Growth

Proceeds from the fundraising will help Novotech pursue M&As, expand into other regions and boost data, AI and tech-related offerings. 

“We are grateful for the support and recognition we received from multiple global investors that participated in the private placement transaction,” said Novotech CEO John Moller. “In addition, we are very pleased to receive continued endorsement from our existing investors. We look forward to accelerating our growth by pursuing various strategic M&A and tech enablement initiatives and seek to better serve our biotech and pharmaceutical clients and support the clinical research industry in the development of a wide spectrum of therapeutic areas.”

Related Article: Are Decentralized Clinical Trials Taking Root in Japan?

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Major U.S. Organization BIO Severs Ties With Member WuXi AppTec Amid U.S. Government’s Security Concerns
2024-03-15
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
2024-01-29
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top